Veterinary Autoimmune Disease Therapeutics Market Report 2025

This Veterinary Autoimmune Disease Therapeutics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The veterinary autoimmune disease therapeutics market size has grown strongly in recent years. It will grow from $3.25 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to advances in immunology, increased pet ownership, improved diagnostic methods, development of new drug classes, and rising awareness of pet health.

The veterinary autoimmune disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in biotechnology, growing investment in veterinary healthcare, increasing prevalence of autoimmune diseases in pets, development of novel therapeutics, and rising pet insurance adoption. Major trends in the forecast period include personalized medicine, the use of biologics, the integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments personalized medicine, use of biologics, integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments.

The increased funding for research in veterinary medicine is anticipated to drive the growth of the veterinary autoimmune disease therapeutics market in the coming years. Veterinary medicine, which focuses on preventing, diagnosing, and treating diseases, disorders, and injuries in animals, is receiving more funding due to various factors such as rising zoonotic diseases, the expanding pet industry, technological advancements in animal health, agricultural needs, and wildlife conservation efforts. This increased funding supports research on veterinary autoimmune diseases, including studies on disease mechanisms, diagnostic tools, and treatment options, thereby enhancing the ability to diagnose and manage these conditions effectively. For example, the National Institute of Food and Agriculture announced the Veterinary Service Grants Program in August 2024, investing $3.2 million in rural food animal veterinary medicine in the fiscal year 2022 across the United States. Hence, the heightened research funding in veterinary medicine is propelling the growth of the veterinary autoimmune disease therapeutics market.

Major companies in the veterinary autoimmune disease therapeutics market are focusing on developing advanced technological solutions, such as RenBiologics, to meet key industry needs. RenBiologics specializes in creating innovative therapies for kidney-related conditions and chronic diseases, with a focus on biologics and regenerative medicine to improve outcomes in areas like renal function and transplant success. For example, in January 2024, Biocytogen, a China-based biotechnology company, launched a new sub-brand, RenBiologics, to focus on the out-licensing of fully human antibodies for therapeutic development. This initiative aims to leverage Biocytogen's extensive library of over 400,000 fully human antibody sequences, created using its proprietary RenMice platform. RenBiologics will support collaborations with pharmaceutical and biotechnology companies for co-development and licensing of these antibodies, advancing the potential for novel antibody-based therapeutics. The launch underscores Biocytogen's commitment to becoming a global leader in antibody discovery and accelerating the development of innovative treatments across multiple therapeutic areas.

In March 2024, AbbVie Inc., a US-based biopharmaceutical company specializing in medicines and solutions for complex health issues, acquired Landos Biopharma for $137.5 million. This acquisition enables AbbVie to expand its portfolio in inflammatory bowel diseases by advancing innovative therapies such as NX-13, addressing significant unmet needs in patient care. Landos Biopharma, also based in the US, focuses on developing autoimmune therapies, with potential applications for treating similar conditions in animals.

Major companies operating in the veterinary autoimmune disease therapeutics market are Pfizer Inc, Merck & Co Inc, AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company, Amgen Inc., Teva Pharmaceuticals Industries Ltd., Zoetis Inc, Boehringer Ingelheim International GmbH, Sumitomo Pharma Co. Ltd., IDEXX Laboratories Inc., Cipla Inc., Mallinckrodt Pharmaceuticals, Virbac S.A, Dechra Pharmaceuticals plc, Neogen Corporation, Vetoquinol S.A., Norbrook Laboratories Limited, Heska Corporation, Bimeda Holdings PLC, Bayer Animal Health Inc, Aratana Therapeutics Inc, Hester Biosciences Limited.

North America was the largest region in the veterinary autoimmune disease therapeutics market in 2024. The regions covered in the veterinary autoimmune disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary autoimmune disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Veterinary autoimmune disease therapeutics encompass treatments tailored to manage and alleviate animal autoimmune conditions. These therapies are geared towards modulating or suppressing the immune response to mitigate inflammation, halt further tissue damage, and enhance the overall well-being and quality of life of affected animals. Given the complexity of these conditions, veterinary autoimmune disease therapeutics necessitate a customized approach, taking into account the specific disease, its severity, and the individual needs of the animal.

The primary types of therapy within veterinary autoimmune disease therapeutics include corticosteroids, azathioprine, cyclosporine, mycophenolate, leflunomide, cyclophosphamide, levothyroxine, folic acid, hydroxychloroquine, and chloroquine. Corticosteroids, derived from steroid hormones produced in the adrenal cortex, are commonly utilized in medicine to diminish inflammation and suppress immune activity. They are administered to various animals, including companion and livestock animals, to address conditions such as disease-type hypothyroidism, pemphigus disease, canine lupus, autoimmune hemolytic anemia, bullous pemphigoid, discoid lupus erythematosus (DLE), immune-related arthritis, among others. These therapeutic agents are typically dispensed through veterinary hospitals and clinics.

The veterinary autoimmune disease therapeutics research report is one of a series of new reports that provides veterinary autoimmune disease therapeutics market statistics, including the veterinary autoimmune disease therapeutics industry's global market size, regional shares, competitors with a veterinary autoimmune disease therapeutics market share, detailed veterinary autoimmune disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary autoimmune disease therapeutics industry. This veterinary autoimmune disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The veterinary autoimmune disease therapeutics market consists of revenues earned by entities by providing immunosuppressive medications, biologic therapies, supportive therapies and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary autoimmune disease therapeutics market also includes sales of prednisone, mycophenolate mofetil, and methotrexate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.